AusperBio to Present Long-Term Follow-Up Data of AHB-137 Treatment in Chronic Hepatitis B in Two Late-Breaking Oral Presentations at AASLD The Liver Meeting® 2026

ConferenceAHB-137Positive

AI Analysis

Summary

AusperBio Therapeutics announced that long-term follow-up data for AHB-137 in chronic hepatitis B treatment has been selected for late-breaking oral presentations at The Liver Meeting 2026.

Clinical Trial Data

Outcome Details

Long-term follow-up data selected for late-breaking oral presentations at The Liver Meeting 2026

Importance:5/10

Sentiment:

0.50

Hepatitis BAHB-137Conference PresentationLate-Breaking DataLong-Term Follow-Up

Read the original article

Published by PR Newswire Pharma on October 8, 2026 12:30 AM

Read Original